RxDoctor Payments Data

Bryn Burnett

Adult Health · Hunt Valley, MDNPI 1518129642

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,448 and has fallen 95.9% since, to $60 in 2025. Among adult health clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,599in general payments, 2019–2025

Across 228 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$547
  • AbbVie$447
  • Saluda Medical Americas, Inc.$348
  • Vertos Medical, Inc.$291
  • Pfizer$258
  • GRT US Holding, Inc.$244
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,599 in reported general payments places this provider in the 90th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$136,425
Medicare patients
168
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate42$34,838
NucyntaTapentadol Hcl14$23,997
OxycontinOxycodone Hcl35$15,261
Nucynta ErTapentadol Hcl13$14,376
Oxycodone Hcl397$9,030
Morphine Sulfate ErMorphine Sulfate181$4,379
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen128$4,361
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen160$4,030
Fentanyl16$3,619
Gabapentin158$2,583
Pregabalin79$2,083
Hydromorphone Hcl50$1,010
Cyclobenzaprine Hcl63$877
Tizanidine Hcl74$573
Tramadol Hcl60$436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Nucynta Er$547$73,21169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 542 adult health providers in Maryland.

Other adult health in Hunt Valley

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →